Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) announced publication of CONVERT trial results evaluating AeriSeal to enable Zephyr Valve treatment in previously ineligible severe emphysema patients. The results appeared online in Respiration: International Journal of Thoracic Medicine.
The prospective study included 101 patients at 14 sites in Europe and Australia. AeriSeal converted collateral ventilation—airflow between lung lobes that can prevent valve treatment from working—to negative status in 75.8% of evaluable patients (75 of 99). Successfully converted patients subsequently received Zephyr Valves. At 45 days after valve placement, 88.9% of evaluable patients achieved clinically significant target lobe volume reduction, which persisted through 12 months. Lung function, quality of life and breathlessness also improved after valve treatment. Pulmonx is enrolling patients in the CONVERT II pivotal trial to evaluate AeriSeal’s safety and effectiveness.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointAeriSeal conversion succeeded in 75.8% of evaluable patients (75 of 99), enabling subsequent Zephyr Valve treatment.
- Moderate pointClinically significant target lobe volume reduction occurred in 88.9% of evaluable patients 45 days after valve placement, persisting through 12 months.
- Minor pointHyperinflation, lung function, quality of life and breathlessness improved following Zephyr Valve treatment.
- Minor pointCONVERT II pivotal trial enrollment is underway to evaluate AeriSeal’s safety and effectiveness.
Negative
- None.
Key Figures
- Study population
- 101 patients
- CONVERT Trial intent-to-treat population
- Investigational sites
- 14 sites
- Europe and Australia
- Lobe conversion rate
- 75.8% (75 of 99)
- Evaluable patients converted from CV+ to CV- after AeriSeal treatment
- Target lobe volume reduction
- 88.9%
- Clinically significant reduction at 45 days after valve placement; persisted through 12 months
Key Terms
collateral ventilation medical
intent-to-treat population medical
bronchoscopic lung volume reduction medical
investigational device exemption (ide) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Study demonstrates potential to enable Zephyr® Valve treatment for selected severe COPD/emphysema patients previously ineligible due to collateral ventilation
REDWOOD CITY, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), today announced the online publication of results from the CONVERT Trial evaluating the AeriSeal® System in patients with severe emphysema and collateral ventilation, in Respiration: International Journal of Thoracic Medicine.
Bronchoscopic lung volume reduction with Zephyr® Endobronchial Valves is effective in patients with little to no collateral ventilation (CV-) in the targeted lung lobe. Collateral ventilation (CV+) allows airflow through openings in the fissures between lung lobes and can prevent a targeted lobe from reducing in volume following valve placement. The CONVERT Trial evaluated whether targeted treatment with the AeriSeal System could close these collateral channels and convert lobes from CV+ to CV- status, potentially enabling subsequent treatment with Zephyr Valves. The CONVERT study was conducted at 14 investigational sites in Europe and Australia and included 101 patients in the intent-to-treat population.
In the prospective, multicenter CONVERT Trial,
Patients who successfully converted were subsequently treated with Zephyr Valves, and results were similar to published results in natively CV- lobes. At 45 days following valve placement,
Patients also experienced improvements in measures of hyperinflation, lung function, quality of life and breathlessness following treatment with Zephyr Valves.
“The CONVERT results are very encouraging because they demonstrate the potential to overcome one of the important barriers preventing patients with severe emphysema from benefiting from bronchoscopic lung volume reduction,” said Michela Bezzi, Director Interventional Pulmonology - ASST Spedali Civili, University Hospital, Brescia, Italy. “By converting collateral ventilation status and then successfully treating these patients with Zephyr Valves, we may be able to offer a minimally invasive treatment option to an additional group of patients who today have limited options.”
“The publication of the CONVERT results represents an important milestone in our efforts to help a larger number of severe emphysema patients who may benefit from Zephyr Valve treatment,” said Glen French, President and Chief Executive Officer of Pulmonx. “CONVERT demonstrated that approximately three out of four evaluable patients could have lobes converted from collateral ventilation positive to collateral ventilation negative status. We are now building on these encouraging findings through CONVERT II, our multinational pivotal Investigational Device Exemption (IDE) trial, as we work toward bringing AeriSeal to patients in the United States.”
CONVERT II Pivotal Trial
Pulmonx is currently enrolling patients in the CONVERT II Pivotal Trial, a multicenter, international study designed to evaluate the safety and effectiveness of the AeriSeal System in treating fissure defects responsible for collateral ventilation in severe COPD/emphysema patients. Patients who successfully convert to CV- status are subsequently treated with Zephyr Valves. Clinical outcomes, including lung volume reduction, lung function, quality of life and exercise capacity, are evaluated following valve treatment.
About the CONVERT Trial
The CONVERT Trial (NCT04559464) was a prospective, open-label, multicenter, single-arm study conducted at 14 sites in Europe and Australia. The study evaluated the safety and effectiveness of the AeriSeal System for converting collateral ventilation status in selected patients with severe emphysema, followed by bronchoscopic lung volume reduction with Zephyr Valves in patients who successfully converted.
About the CONVERT II Pivotal Trial
The CONVERT II Pivotal Trial (NCT06035120) is a multinational pivotal study evaluating the safety and effectiveness of the AeriSeal System in patients with severe COPD/emphysema and collateral ventilation. The study is designed to enroll approximately 200 patients in the United States and internationally, with six-month results intended to support a U.S. Food and Drug Administration Premarket Approval (PMA) application for the AeriSeal System. The study is being conducted under an Investigational Device Exemption (IDE) and is intended to support a U.S. Premarket Approval (PMA) application for the AeriSeal System.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX® Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, LungTraX®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding enrollment in and the design, timing, conduct, results and potential clinical or regulatory impact of the CONVERT II Pivotal Trial; the Company’s plans to use six-month results from CONVERT II to support a Premarket Approval application for the AeriSeal System; the timing, review or outcome of any regulatory submission; and the potential for the AeriSeal System to enable Zephyr Valve treatment for additional patients with severe emphysema. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.
Investor Contact
Brian Johnston or Webb Campbell
Gilmartin Group
investors@pulmonx.com
Media Contact
Marcee Maroney
Pulmonx Corporation
mmaroney@pulmonx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pulmonx’s CONVERT trial show about AeriSeal?
AeriSeal converted collateral ventilation from positive to negative status in 75.8% of evaluable patients (75 of 99). Patients who successfully converted subsequently received Zephyr Valves. At 45 days after valve placement, 88.9% of evaluable patients achieved clinically significant target lobe volume reduction, which persisted through 12 months.
What is Pulmonx evaluating in the CONVERT II pivotal trial?
CONVERT II evaluates AeriSeal’s safety and effectiveness in treating fissure defects responsible for collateral ventilation in severe COPD/emphysema patients. Patients who successfully convert to negative collateral ventilation status subsequently receive Zephyr Valves. Outcomes evaluated after valve treatment include lung volume reduction, lung function, quality of life and exercise capacity.